Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus.

Area of Science:

• Rheumatology and Neurology
• Investigating the complex interplay between autoimmune disease and neurocognitive outcomes.

Background:

• Systemic lupus erythematosus (SLE) frequently presents with both cognitive dysfunction and cardiovascular disease.
• Understanding predictors of cognitive impairment is crucial for managing SLE patients.
• Previous research highlights the need to explore both traditional and SLE-specific risk factors.

Purpose of the Study:

• To evaluate the relationship between cardiovascular events, traditional cardiovascular risk factors, and SLE-specific risk factors in predicting cognitive dysfunction.
• To identify key variables associated with cognitive impairment in a large cohort of SLE participants.

Main Methods:

• Utilized data from 694 participants in the longitudinal Lupus Outcomes Study (LOS).
• Assessed cognitive function using the Hopkins Verbal Learning Test-Revised and Controlled Oral Word Association Test.
• Employed multiple logistic regression to analyze associations between cognitive impairment and risk factors including antiphospholipid antibodies (aPL), hypertension, and history of stroke.

Main Results:

• Fifteen percent of SLE participants exhibited cognitive impairment.
• Antiphospholipid antibodies (aPL) (OR 2.10), hypertension (OR 2.06), and a history of stroke (OR 2.27) were significantly associated with cognitive dysfunction.
• Stroke was more prevalent in patients with severe cognitive impairment (P = 0.036).

Conclusions:

• Antiphospholipid antibodies (aPL), hypertension, and a history of stroke are significant predictors of cognitive impairment in SLE.
• These findings can help identify SLE patients at higher risk for cognitive dysfunction.
• Further research can guide targeted interventions for cognitive health in SLE.